IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients

Purpura, Thrombotic Thrombocytopenic Clinical Trial

Official title:

A Phase II Pilot Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients With Low ADAMTS13 Activity

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02854059
• Other study ID #: 15-HMedIdeS-08
• Status: Terminated
• Phase: Phase 2
• Start date: September 2016
• Est. completion date: January 2017

Study information

• Verified date: September 2019
• Source: Hansa Biopharma AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate safety and tolerability in patients diagnosed with asymptomatic antibody-mediated TTP with low ADAMTS13 activity after receiving single intravenous dose of IdeS.

Description:

Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) is an IgG specific endopeptidase which cleaves IgG molecules and efficiently neutralizes Fc-mediated activities. IdeS-mediated IgG degradation constitutes a novel therapeutic principle for the treatment of IgG-driven human diseases.

In addition to assessing the safety and tolerability of IdeS the study will also assess the efficacy of IdeS to significantly increase the ADAMTS13 activity and decrease the anti-ADAMTS13 antibody levels in patients diagnosed with asymptomatic antibody-mediated TTP with low ADAMTS13 activity.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or above

• Diagnosed with acquired TTP with ADAMTS13 levels of = 10 % in clinical remission and with measurable or previously confirmed ADAMTS13 antibodies

Exclusion Criteria:

• Prior malignancy within 5 years

• Test positive for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV)

• Ongoing infectious disease including P-CRP >10

• Test positive for IgE antibodies against IdeS

• Secondary cause of TTP

• Rituximab treatment or other antibody-based therapy within 7 days prior to IdeS dosing

• Treatment with investigational medicinal product within the last 12 weeks proceeding screening

• Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure > NYHA (New York Heart Association) grade 3, unstable coronary disease or oxygen dependent COPD

• History of any other clinically significant disease or disorder which may either put the patient at increased risk because of participation in the study, or influence the results or the patient's ability to participate in the study

• Hypogammaglobulinemia defined as any values of P-total IgG less than 3 g/L

• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to IdeS (e. g. streptokinase and/or staphylokinase)

• Substance abuse or other concurrent medical condition that could confound study interpretation or affect the patient's ability to tolerate or complete the study

• Breast feeding women or women with a positive pregnancy test

• Previously received IdeS treatment

Related Conditions & MeSH terms

• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombotic Thrombocytopenic

Intervention

Biological:
• IdeS (0.25 mg/kg)
Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
• IdeS (0.50 mg/kg)
Single i.v. infusion of IdeS (0.50 mg/kg).

Locations

Country	Name	City	State
United Kingdom	University College London Hospitals NHS	London	Greater London

Sponsors (2)

Lead Sponsor	Collaborator
Hansa Biopharma AB	University College London Hospitals

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Tolerability as Measured by Type, Frequency and Intensity of Adverse Events	Data on AEs were obtained if spontaneously reported by the patient, if reported in response to an open question from the study personnel or if revealed by observation.; A treatment emergent AE (TEAE) is defined as any AE occurring after administration of the IMP and within the time of the residual drug effect period (i.e. 30 days after IMP administration).; AEs reported in ClinicalTrials.gov include TEAEs and post-treatment AEs, i.e. all AEs occurring after administration of IdeS until end of study.; Please refer to Adverse Event section for details on reported AEs	From dosing until end of follow up on day 64
Secondary	Number of Patients With Change From Baseline in ADAMTS13 Activity	ADAMTS13 is an enzyme which is inhibited in patients with TTP. The efficacy of IdeS on ADAMTS13 activity was measured througout the study as change from baseline.	From day of dosing until end of follow up on day 64
Secondary	Number of Patients With Change From Baseline in ADAMTS13 Antibody Levels	The efficacy of IdeS on ADAMTS13 antibody cleaving was measured througout the study as change from baseline in ADAMTS13 antibody concentration.	From day of dosing until end of follow up on day 64
Secondary	Number of Patients for Whom a Decreased ADAMTS13 Activity Returned to Normal Levels at Different Time-points in the Study	The ADAMTS13 activity in TTP patients is decreased. The efficacy of IdeS on ADAMTS13 activity was assessed throughout the study to identify the time-point of return to normal levels.	From day of dosing until end of follow up on day 64
Secondary	Number of Patients With Change From Baseline in Pharmacodynamics as Measured by Level of IgG	IdeS cleaves IgG molecules. The concentration of uncleaved IgG in the patient's serum was measured throughout the study to determine change from baseline following IdeS administration.	From day of dosing until end of follow up on day 64
Secondary	Number of Patients Showing IdeS Immunogenicity as Measured by Anti-drug Antibodies	Most humans have been infected with S. pyogenes which is the origin of IdeS. It was therefore expected that patients in this study might have antibodies against IdeS before being exposed to IdeS in the study. The concentration of ant-IdeS antibodies was measured before dosing and throughout the study.	From day of dosing until end of follow up on day 64
Secondary	Maximum Serum Concentration (Cmax) of IdeS	The concentration of IdeS in serum was measured to identify the pharmacokinetic parameter Cmax of IdeS in TTP patients.	From day of dosing until day 14
Secondary	Time-point for Maximum Serum Concentration of IdeS	The concentration of IdeS in serum was measured to identify the pharmacokinetic parameter Tmax of IdeS in TTP patients. Tmax refers to the time-point when the serum concentration of IdeS reaches maximum.	From day of dosing until day 14
Secondary	Number of Patients With Change From Baseline in Pharmacodynamics as Measured by Level of F(ab')2 Fragments	The efficacy of IdeS can be measured as change from baseline in F(ab')2 fragments (i.e. the antigen binding fragment of IgG).	From day of dosing until end of follow up on day 64